Strategic Growth Worldwide is actively expanding through acquisitions and leadership changes, presenting opportunities to cross-sell services to Catalyst Clinical Research clients and to align with new executive goals and integration programs.

Expanded Capabilities Recent asset sales and divestitures indicate a refocused portfolio; identify clients seeking deeper specialized pharmacology, bioanalytical, and Phase II–III CRO support to fill gaps created by the sale.

Senior Leadership New CEO appointments and board changes signal potential shifts in strategic priorities; engage at the executive level to position full-service and Worldwide Flex offerings as scalable, decision-support driven outsourcing alternatives.

M&A Ready Acquisition of Catalyst Clinical Research expands contract scope and customer base; target both former Catalyst clients and overlapping biopharma programs needing integrated trial management and data transparency.

Global Scale With operations in over 70 countries and a diverse therapeutic focus, present multi-region, program-level solutions that emphasize consistent governance, trial conduct, and cross-border data handling to prospective sponsors prioritizing global trials.